OTLK Company Profile and Key Details

OTLK has shown weak momentum, losing -9.44% over the past week and -60.31% over the past quarter, though year-to-date performance is down -67.09%. Short-term trend indicators are bullishly aligned (SMA20 1.02%, SMA50 -48.54%, SMA200 -70.2%). The stock’s 14-day RSI is 38.56 (weak momentum), while the ATR of 0.06 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -87.22% below its high and over 14.0% above its low. Average 10-day trading volume of 3.31 million shares is below the 3-month average of 13.85 million, indicating normal recent market interest.

Outlook Therapeutics, Inc. has 242.67 million shares outstanding. The public float is 196.11 million shares, elevated short interest at 11.54% of float. This equals 20.01 million shares. The short ratio is 1.44 days. Institutional investors hold 7.06% of the float. Insiders own 14.92%. Mohan Pankaj holds 7.06 million shares, Sukhtian Ghiath M. has 2.53 million shares and Syntone Ventures LLC has 1.07 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Outlook Therapeutics, Inc. generated EPS of -$1.09 over the past year. Five-year average earnings growth is 33.18%. Wall Street analysts project EPS growth of 56.24% annually over the next five years. The latest quarter delivered EPS of -$0.14. The next quarter is forecast at -$0.17. Next year's EPS is expected at $33.33. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 4 Buy ratings, 6 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $10.00 to $0.50. The high target offers 1462.5% upside. The low target suggests -21.88% downside. The mean target is $4.21. This offers 557.81% upside. Outlook Therapeutics, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended August 14, 2026, missed forecasts by 75.0%. The prior quarter beat by 75.0%. Over the last six quarters, Apple has recorded several small beats. These include 4.76% in August 14, 2025.

Outlook Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.13. This means the shares are trading below this model’s fair value.

Outlook Therapeutics, Inc. (NASDAQ:OTLK) closed at $0.64 USD, losing -$0.02 (-2.49%) from the previous close of $0.66. The stock is currently mid-range between its 52-week high and low $0.16 and $2.54. With a market capitalization of about $119.58 million, Outlook Therapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.75). Key stats such as the average daily volume over the past year has been around 13.77 million shares, volume is running light vs its 52-week average. Headquartered in Iselin, NJ, Outlook Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Robert Charles Jahr, the company employs approximately 17 people and listed since June 14, 2016. Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions.

Outlook Therapeutics, Inc. trades at a P/E ratio of -0.34, slightly below the S&P 500 average, with a price-to-sales ratio of -102.81 and a price-to-book ratio of -1.57 indicating negative book value, which may reflect financial stress. The P/FCF stands at -2.09, also below market averages.

Our AI price prediction model suggests that Outlook Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -15.56%, with price expected at $0.54 by October 09, 2026, within a range of $0.39 to $0.69 3-Month Outlook: Projected rise of 494.21%, reaching $3.80 by December 24, 2026, with a range of $3.30 to $4.23. 1-Year Outlook: Projected loss of -31.2%, with price at $0.44 by September 24, 2027, within a range of $0.00 to $0.50.

Outlook Therapeutics, Inc. (NASDAQ:OTLK) shares are down -67.09% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Outlook Therapeutics, Inc. trading at a premium to the broader market with a P/E of -0.34. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $10.63, suggesting 1562.24% upside. Our AI forecast model points to short-term weakness (-15.56% over two weeks), a medium-term rise (494.21% over three months), and a longer-term loss (-31.2% over one year), with expected trading ranges indicating moderate volatility.